---
title: "Scinai Immunotherapeutics tumbles 8%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303049100.md"
description: "Scinai Immunotherapeutics fell 8.26% to US$0.5179. Down 55.35% over ten sessions and down 92.73% YTD."
datetime: "2026-10-26T13:38:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303049100.md)
  - [en](https://longbridge.com/en/news/303049100.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303049100.md)
generator: "portal-rs"
---

# Scinai Immunotherapeutics tumbles 8%

Scinai Immunotherapeutics (SCNI.US) tumbled more than **8%** during regular trading to **$0.5179**.

The stock is down 55.35% over the past ten sessions and down 92.73% year to date. It sits 96.66% below its 52-week high of US$15.49. Volume was 6.01 times its average.

The Nasdaq Composite is down 1.32% over the past five sessions and up 12.22% year to date.

The company completed a private placement and warrant inducement transaction totaling approximately $4 million on Oct. 16, 2026, issuing American depositary shares or pre-funded warrants to an institutional investor. The proceeds will be used to advance its contract development and manufacturing organization projects and immunotherapy pipeline.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [SCNI.US](https://longbridge.com/en/quote/SCNI.US.md)

## Related News & Research

- [Scinai Immunotherapeutics Extends Cash Runway on New CDMO Deal and October Financing](https://longbridge.com/en/news/302438355.md)
- [Scinai Immunotherapeutics Ltd. (SCNI) Secures $5.1M CDMO Work, Runway to Late 2027](https://longbridge.com/en/news/302424934.md)
- [Is SpaceX Stock Worth Buying While It's Below $140?](https://longbridge.com/en/news/304084857.md)
- [IonQ Stock Earnings Preview: What to Expect After Its Record Second Quarter](https://longbridge.com/en/news/304113732.md)
- [Google Says Demand Will Swallow Every Data Center It Builds](https://longbridge.com/en/news/303998103.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**